Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Anand Veerapathran"'
Autor:
David McDermott, Virginia Seery, Rupal Bhatt, Adrian Wells, Mamta Gupta, Brian Halbert, David Einstein, Emanuelle Andrianopoulos, Kenneth Onimus, Courtney Herman, Shwetha Lakshmipathi, Arvind Natarajan, Anand Veerapathran
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/ac294b04595448f389f6a445c691e5f3
Autor:
Arvind Natarajan, Anand Veerapathran, Adrian Wells, Kenneth Onimus, Marcus Machin, Seth Wardell, Jamie L. Blauvelt, Madan Jagasia, Rafael Cubas
Publikováno v:
Cancer Research. 82:2746-2746
Background: Adoptive cell therapy with autologous TIL has demonstrated an objective response rate (ORR) of 36% in the post-immune checkpoint inhibitor (ICI) setting in patients (pts) with advanced/unresectable melanoma (Sarnaik JCO 2021), while in IC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0935057c07b99c068888f49dc1cb381
https://doi.org/10.1158/1538-7445.am2022-2746
https://doi.org/10.1158/1538-7445.am2022-2746
Autor:
Adrian Wells, Arvind Natarajan, Anand Veerapathran, Shwetha Lakshmipathi, Courtney Herman, Joe Wypych, Viktoria Gontcharova, Nermin Gerges, Kenneth Onimus
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A110-A110
BackgroundLifileucel (LN-144) and LN-145, adoptive cell therapies using autologous tumor-infiltrating lymphocytes (TIL), have demonstrated encouraging efficacy with acceptable safety in a variety of tumor types.1–4 The lifileucel Gen 2 clinical man
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1a58a9d933f5d375697407128d120cc
https://doi.org/10.1136/jitc-2021-sitc2021.101
https://doi.org/10.1136/jitc-2021-sitc2021.101
Autor:
Brian Halbert, David Einstein, David McDermott, Emanuelle Andrianopoulos, Mamta Gupta, Virginia Seery, Kenneth Onimus, Courtney Herman, Adrian Wells, Shwetha Lakshmipathi, Arvind Natarajan, Anand Veerapathran, Rupal Bhatt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPatients with RCC may achieve remission with immune-checkpoint inhibitors (ICI); however, most patients will progress. Adoptive cell therapy with autologous TIL allows for expansion of T-cells from tumor tissue leading to a polyclonal T-cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b0f7e44e3bde4ea1e72ec0df4f22c31
https://doi.org/10.1136/jitc-2021-sitc2021.176
https://doi.org/10.1136/jitc-2021-sitc2021.176
Autor:
Amit A. Lugade, Cecile Chartier, Elizabeth Brese, Adrian Wells, Maria Fardis, Anand Veerapathran, Arvind Natarajan, Gurkamal Chatta, Kunle Odunsi, Qiang J. Li, Khurshid A. Guru, Kenneth Onimus
Publikováno v:
Clinical Cancer Research. 26:A05-A05
Background: Patients with advanced bladder cancer have limited therapeutic options, apart from cisplatin-based chemotherapy and use of immune checkpoint inhibitors (ICI). Median survival for patients with metastatic disease is 15 to 18 months. Hence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::365f840355ebbb312b91110403afb98d
https://doi.org/10.1158/1557-3265.bladder19-a05
https://doi.org/10.1158/1557-3265.bladder19-a05
Autor:
Krit Ritthipichai, Marcus Machin, Michelle Simpson-Abelson, Christopher Mosychuk, Anand Veerapathran, Michael Lotze
Publikováno v:
The Journal of Immunology. 198:198.1-198.1
Only two K+ channels are known to be expressed by T-cells. Activated effector T cells express high levels of Kv1.3; activated naïve and central memory T-cell subsets express high levels of KCa3.1. Overexpression of Kv1.3 in murine T-cells increases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1eeecbe7781227d61071c9fd9fb1973e
https://doi.org/10.4049/jimmunol.198.supp.198.1
https://doi.org/10.4049/jimmunol.198.supp.198.1